ArticleUrology2017
A Pilot Study of a Multimodal Treatment Paradigm to Accelerate Drug Evaluations in Early-stage Metastatic Prostate Cancer.
Article in Urology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.
- Is there a role for radical prostatectomy in the management of oligometastatic prostate cancer? A systematic review.Prostate cancer and prostatic diseases · 2024Pooled it
- Accelerating Drug Development in Hormone-Naïve Prostate Cancer through Multimodal Therapy Strategies: The MetaCURE Phase 2 Randomized Clinical Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Prognostic and predictive analyses of circulating plasma biomarkers in men with metastatic castration resistant prostate cancer treated with docetaxel/prednisone with or without bevacizumab.Prostate cancer and prostatic diseases · 2025Trial
- Systemic and Tumor-directed Therapy for Oligometastatic Prostate Cancer: The SOLAR Phase 2 Trial in De Novo Oligometastatic Prostate Cancer.European urology · 2024Trial
- Systemic and Tumor-directed Therapy for Oligorecurrent Metastatic Prostate Cancer (SATURN): Primary Endpoint Results from a Phase 2 Clinical Trial.European urology · 2024Trial
- Interim analysis of companion, prospective, phase II, clinical trials assessing the efficacy and safety of multi-modal total eradication therapy in men with synchronous oligometastatic prostate cancer.Medical oncology (Northwood, London, England) · 2022Trial
- Primary site- and metastasis-directed therapies in patients with metastatic prostate cancer: A narrative review.International journal of clinical oncology · 2026Review
- Exploring treatment models for oligometastatic castration-sensitive prostate cancer: evolution of therapeutic strategies.Frontiers in oncology · 2026Review
- [Metastasis-directed therapy in prostate cancer].Urologie (Heidelberg, Germany) · 2024Review
- Improved survival of patients with newly diagnosed oligometastatic prostate cancer through intensified multimodal treatment.Frontiers in oncology · 2024Article
- The diagnosis and treatment of castrate-sensitive oligometastatic prostate cancer: A review.Prostate cancer and prostatic diseases · 2023Review
- Review
- Genomic analysis and long-term outcomes of a phase 1 clinical trial on cytoreductive radical prostatectomy.Prostate international · 2022Article
- Where Do We Stand in the Management of Oligometastatic Prostate Cancer? A Comprehensive Review.Cancers · 2022Review
- A first case of ductal adenocarcinoma of the prostate having characteristics of neuroendocrine phenotype with PTEN, RB1 and TP53 alterations.BMC medical genomics · 2021Article
- Article
- Multidisciplinary Therapy in Men with Newly Diagnosed Oligometastatic Prostate Cancer.Research and reports in urology · 2021Article
- Multidisciplinary total eradication therapy (TET) in men with newly diagnosed oligometastatic prostate cancer.Medical oncology (Northwood, London, England) · 2020Article
- Harnessing the potential of multimodal radiotherapy in prostate cancer.Nature reviews. Urology · 2020Review
- Cytoreductive treatment strategies for de novo metastatic prostate cancer.Nature reviews. Clinical oncology · 2020Review
Corrections and comments
- Commented on by
Authors and funding
17 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveTo evaluate a multimodal strategy aimed at treating all sites of disease that provides a rapid readout of success or failure in men presenting with non-castrate metastatic prostate cancers that are incurable with single modality therapy. MATERIALS AND
methodsTwenty selected men with oligometastatic M1a (extrapelvic nodal disease) or M1b (bone disease) at diagnosis were treated using a multimodal approach that included androgen deprivation, radical prostatectomy plus pelvic lymphadenectomy (retroperitoneal lymphadenectomy in the presence of clinically positive retroperitoneal nodes), and stereotactic body radiotherapy to osseous disease or the primary site. Outcomes of each treatment were assessed sequentially. Androgen deprivation was discontinued in responding patients. The primary end point was an undetectable prostate-specific antigen (PSA) after testosterone recovery. The goal was to eliminate all detectable disease.
resultsEach treatment modality contributed to the outcome: 95% of the cohort achieved an undetectable PSA with multimodal treatment, including 25% of patients after androgen deprivation alone and an additional 50% and 20% after surgery and radiotherapy, respectively. Overall, 20% of patients (95% confidence interval: 3%-38%) achieved the primary end point, which persisted for 5, 6, 27+ , and 46+ months. All patients meeting the primary end point had been classified with M1b disease at presentation.
conclusionA sequentially applied multimodal treatment strategy can eliminate detectable disease in selected patients with metastatic spread at diagnosis. The end point of undetectable PSA after testosterone recovery should be considered when evaluating new approaches to rapidly set priorities for large-scale testing in early metastatic disease states and to shift the paradigm from palliation to cure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.